Commercial Leadership Has Become the New Value Creation Lever in Pharmaceutical Services

For years, growth in pharmaceutical services was fueled by acquisitions. Private equity firms built platforms through aggressive M&A strategies, using bolt-on acquisitions to accelerate revenue, expand capabilities, and increase enterprise value. Today, that playbook has become far more difficult to execute. While investor appetite for pharmaceutical services remains strong, challenging exit conditions have slowed deal activity across the sector. As a result, many portfolio companies are increasingly turning to commercial leadership to drive growth. 

From Growth to Gridlock: Five Years of Change in PE-Backed Pharmaceutical Services 

The market conditions that have unfolded over the past five years have created a perfect storm for today’s sluggish deal environment. Immediately following the COVID-19 pandemic, private equity investment in pharmaceutical services surged. As confidence returned to the market and capital became readily available, investors poured money into the sector, driving intense competition for high-quality assets. Basic supply and demand dynamics took hold, ultimately leading to rapidly expanding valuation multiples and seller expectations. 

Today, investor interest in the sector has not disappeared. On the contrary, pharmaceutical services remains one of the most attractive healthcare investment categories. What has changed is the market’s ability to support transactions. Elevated asking prices, combined with already inflated acquisition multiples, have made it increasingly difficult for private equity firms to identify deals with a credible path to creating additional enterprise value. Buyers remain eager to invest, but the combination of scarce, high-quality assets and pricing expectations has significantly slowed deal activity. 

Many firms now find themselves four to five years into their investment cycle with fewer viable exit opportunities than anticipated. At the same time, the acquisition strategies that fueled growth during the post-pandemic boom have become far more difficult to execute. Bolt-on acquisitions are harder to source, more expensive to complete, and often less compelling from a value creation standpoint. Rather than relying on M&A to accelerate growth, companies are increasingly turning inward to maximize value. 

This shift has dramatically increased the pressure on commercial leadership to perform. Organic growth has become the primary lever for increasing enterprise value. Thus, for boards and investors, having the right commercial leadership team in place has become a strategic imperative. The right go-to-market executive can unlock organic growth, strengthen competitive positioning, and create the performance needed to support a successful exit when market conditions improve. 

How Do You Evaluate Your Current Commercial Leadership? 

The first challenge investors and boards must solve is whether their current commercial leadership has truly reached its ceiling, or simply needs more time. 

There are three clear signals that it may be time for a change: 

1. A lack of strategic innovation: If commercial performance is flat and the strategy hasn’t meaningfully changed, the leader may have run out of ideas. Strong commercial leaders will continuously adapt, refining positioning, exploring new segments, or rethinking go-to-market models. When that stops, growth often does too. 
2. A disengaged or unresponsive team: When a commercial team becomes slow to execute, it can signal declining confidence in leadership and a lack of belief in the direction being set. If the team no longer believes in the commercial leader, you shouldn’t either. 
3. Resistance to innovation: Whether it’s data-driven selling, digital processes, AI, or other tools, your commercial leader should be jumping in two feet first to embrace new technology and ways of working. Go-to-market leaders who dismiss or delay adoption risk falling behind – and so do the organizations that employ them. 

If your commercial leader has pivoted the strategy, the team is still on board, and new tools are being adopted regularly, it is likely the leader simply needs more time. However, if these circumstances are not true, the next step is identifying the right go-to-market leader for the job. 

How Do You Evaluate Prospective Commercial Leadership? 

Unfortunately, many of the strongest commercial executives today have resumes that include multiple short tenures. In recent years, evolving market conditions have compelled even high-performing professionals to transition between roles with greater frequency. Thus, it is imperative to distinguish between top talent navigating a volatile environment and underperformers who are driven into repeated transitions. 

When evaluating leaders with this background, boards and investors should follow a thoughtful, thorough vetting process. This will include multiple reference checks, both with the formal references the candidate provides, as well as “backchannel” references, or individuals who can provide confidential insight into the candidate’s performance.  

Furthermore, meticulous probing during the interview process is critical. In addition to performance and character, boards and investors must vet every single role change the candidate made and get a clear reason why they left. If any negative patterns or unanswered questions emerge, this is cause for concern. Of course, some departures are confidential or contentious through no fault of the candidate, but thoroughly understanding each move is vital. 

Given the critical nature of go-to-market leadership in ensuring the success of today’s pharmaceutical services companies, taking the time to land the right candidate is a worthwhile investment. An internal talent partner may be the best resource to find the right go-to-market leader, but turning to an external executive search expert can also be highly effective and reduce the amount of time and effort it takes investors to get the right leader in the seat. 

How Do You Retain Top Commercial Talent? 

Once you have the right commercial leadership in place, retention presents an ongoing challenge. Compensation and incentive structure are critical in today’s more challenging business environment. When commercial teams are unable to achieve their variable compensation, they are bound to look for new opportunities. To retain top commercial talent, leading companies should focus on structuring compensation and incentives to reward and engage commercial leadership even in a down or stagnant market. 

In addition to a competitive compensation package, a growing driver of turnover among commercial leaders is the organization’s approach to innovation, particularly AI. High performers want to operate in environments that are forward-looking. If they perceive that a company is moving too slowly, investing too cautiously, or lacking a clear point of view on AI, they are more likely to explore other opportunities. 

Steps pharmaceutical services businesses should take to embrace AI: 

• Engrain AI into the strategy
  Organizations don’t need to adopt every new tool, but they do need a well-defined and future-focused approach to AI. A lack of clear strategic direction or indecision around AI from the CEO or COO can be indicative of a lack of future planning. High-performing go-to-market leaders will leave opportunities where top leadership is not building AI into the strategy. 

• Engage commercial leadership in shaping the AI approach
  Strong commercial leaders will bring informed perspectives on how AI can enhance targeting, productivity, and customer engagement. Involving them in decision-making will build alignment, commitment, and ensure they are invested in building the future of the company. Failing to do so will likely leave them increasingly disengaged and escalate flight risk.   

In a market where exits are delayed, commercial performance has become the defining factor in value creation. Do you have the leadership required to drive organic growth in this demanding environment? If you can’t definitively say yes, waiting to make a change might be the riskiest choice.